
1. best pract res clin haematol. 2018 sep;31(3):279-284. doi:
10.1016/j.beha.2018.07.013. epub 2018 jul 23.

burkitt lymphoma- rare challenging lymphoma.

casulo c(1), friedberg jw(2).

author information: 
(1)james p. wilmot cancer institute, university rochester medical center, 601 
elmwood avenue box 704, rochester, ny, 14642, usa. electronic address:
carla_casulo@urmc.rochester.edu.
(2)james p. wilmot cancer institute, university rochester medical center, 601 
elmwood avenue box 704, rochester, ny, 14642, usa.

burkitt lymphoma (bl) rare, aggressive subtype non-hodgkin lymphoma
affecting approximately 1500 patients per year. three forms bl exist
(sporadic, endemic, immunodeficiency associated) endemic form first
discovered driven epstein barr virus areas world 
malaria prevalent. bl characteristic t8; 14 cytogenetic translocation 
that leads constitutive activation myc gene, drives bl cell
division. therapy bl resulted cure many patients significant
toxicity treatment related complications remains problematic approach 
to bl therapy. treatment options relapsed refractory disease remain
limited however novel treatments studied block myc activation, and
cold lead promising options patients relapsed refractory disease.

copyright Â© 2018 elsevier ltd. rights reserved.

doi: 10.1016/j.beha.2018.07.013 
pmid: 30213397  [indexed medline]

